Royality Med's is benefiting from more than a decade of cutting-edge basic research at the interface between human stem cell biology and physics. We are a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. We have created an exciting human organoid-based platform that can be used for agnostic drug discovery and uniquely can be translated at the level of high-throughput screening.
Royality Med's was founded in 1997 to build on our world leading position in the research and development of a portfolio of patented molecules with unique mechanisms of action that affect the biologic pathways in the body related to the diseases we are targeting.